Answers are grounded in this paper and cite their sources.
This present study evaluated the effects of a commercial formulation based on fenthion on survival, hatching, and growth of Artemia salina, and characterized the environmental risk of this insecticide to marine and estuarine ecosystems. The fenthion-based commercial formulation was tested at concentrations ranging from 0.001 up to 731 mg/L using different bioassays: a standard 48-h acute test, a 14-day long-term test, and also two 72-h assays (one for cyst hatching, another for growth inhibition). Obtained EC50 values were fully integrated with available literature data to construct a species sensitivity distribution (SSD) curve, which then determined the hazardous concentration for 5% of species (HC5), the predicted no-effect concentration (PNEC), and the risk quotient (RQ). In the acute assay, the formulation showed low toxicity, with EC50 of 212.36 mg/L at 24 h and 16.64 mg/L at 48 h. In contrast, high toxicity was observed in long-term tests, with EC50 of 0.0752 mg/L after 8 days and 0.0052 mg/L after 14 days of exposure. Minor effects were observed on hatching rate (EC50 = 101.75 mg/L), whereas more pronounced effects were seen on hatching speed (EC50 = 19.88 mg/L) and nauplii growth (EC10 = 0.076 mg/L). The HC5 from the SSD was 0.000104 mg/L, while PNEC was 0.000020 mg/L. The average RQ was 1.86, indicating high risk. Overall, these results demonstrate the ecotoxicological potential of a fenthion-based commercial formulation for relevant organisms in marine and estuarine ecosystems, reinforcing the importance of regulatory measures and environmental monitoring in areas subject to contamination by this insecticide.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: